Olmesartan Comparison to Losartan in Hypertensive Subjects

ClinicalTrials.gov ID: NCT00949884

Public ClinicalTrials.gov record NCT00949884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy and safety of the FDA approved blood pressure medication olmesartan medoxomil compared to the FDA approved medication losartan potassium.

Study identification

NCT ID: NCT00949884
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 941 participants

Conditions and interventions

Conditions

Hypertension

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2009
Primary completion: Dec 31, 2009
Completion: Dec 31, 2009
Last update posted: Mar 8, 2011

2009 – 2010

United States locations

U.S. sites: 20
U.S. states: 15
U.S. cities: 20

Facility	City	State	ZIP	Site status
Not listed	Mesa	Arizona	85213	—
Not listed	Phoenix	Arizona	85050	—
Not listed	Harbor City	California	90710	—
Not listed	Tustin	California	92780	—
Not listed	Westlake Village	California	91361	—
Not listed	Pueblo	Colorado	81001	—
Not listed	Deerfield Beach	Florida	33442	—
Not listed	DeLand	Florida	32720	—
Not listed	South Bend	Indiana	46614	—
Not listed	Wichita	Kansas	67205	—
Not listed	Metairie	Louisiana	70006	—
Not listed	Albuquerque	New Mexico	87108	—
Not listed	Binghamton	New York	13701	—
Not listed	Charlotte	North Carolina	28209	—
Not listed	Cincinnati	Ohio	45219	—
Not listed	Greenville	South Carolina	29615	—
Not listed	Bristol	Tennessee	37620	—
Not listed	New Tazewell	Tennessee	37825	—
Not listed	Dallas	Texas	75230	—
Not listed	Norfolk	Virginia	23502	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00949884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 8, 2011 · Synced Sep 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00949884 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →